Tech Company Financing Transactions
Tyrogenex Funding Round
Brace Pharma participated in a $15 million Series D funding round for Tyrogenex. The round was announced on 6/20/2014.
Transaction Overview
Company Name
Announced On
6/20/2014
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series D
Investors
Proceeds Purpose
The funding from the Series D will support further clinical development of X-82, including a phase 2, randomized study of X-82 as an oral treatment of wet age-related macular degeneration (AMD) that is expected to begin later this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
197 1st Ave. 330
Needham Heights, MA 02494
USA
Needham Heights, MA 02494
USA
Phone
Website
Email Address
Overview
Founded in 2006, Tyrogenex is comprised of an experienced team that is dedicated to advancing next generation targeted therapeutics as promising new treatments to improve the lives of cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
Chris Liang
VP - Operations
Kimberly Harrow
Browse more venture capital transactions:
Prev: 6/20/2014: Western Oncolytics venture capital transaction
Next: 6/20/2014: Airspan Networks venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs